ºÚÁϳԹÏÍø

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ºÚÁϳԹÏÍø News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Dec 13 2018

Full Issue

Blue Cross And Blue Shield Insurers Dealt Significant Legal Blow In Case Over Anti-Competitive Practices

The ruling makes it easier for providers and plan members to prove that the plans impede competition by offering insurance coverage in exclusive markets.

A federal appeals court on Wednesday ruled that Blue Cross and Blue Shield insurers must defend themselves against a major class action case accusing them of anticompetitive practices on much less favorable legal grounds. The 11th U.S. Circuit Court of Appeals upheld a federal district judge's April ruling that the combination of the Blues plans' exclusive territories, in which they agreed not to compete, and the agreement to limit competition on non-Blues branded products is a per se violation of the Sherman Antitrust Act. (Meyer 12/12)

In other health industry news —

UnitedHealth Group Inc., the biggest U.S. health insurer, agreed to renew its contract with a large hospital staffing company after a months-long stand-off that threatened to put millions of people at risk of surprise medical bills. The contract between UnitedHealth’s insurance unit and Envision Healthcare, owned by private-equity giant KKR & Co., was set to expire Jan. 1. The companies announced the deal in separate press releases Tuesday morning. Representatives for UnitedHealth and Envision both declined to comment on details of the new agreement. (Tozi, 12/11)

Johnson & Johnson is willing to pay more than $400 million to settle some of the thousands of consumers’ allegations that the company sold defective artificial hips and hid the health risks of the devices, people familiar with the negotiations said. The world’s largest health-care products maker has settled, or is in the process of settling, about 3,300 of 10,000 lawsuits targeting its Pinnacle line of hip-replacement devices, a judge said in a Dec. 9 court filing. (Feeley, 12/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ºÚÁϳԹÏÍø
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF